FY2024 EPS Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO) Lowered by Analyst

Spero Therapeutics, Inc. (NASDAQ:SPRO) – Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Spero Therapeutics in a note issued to investors on Tuesday, August 6th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($1.69) per share for the year, down from their previous forecast of ($1.19). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.27) per share.

SPRO has been the subject of a number of other reports. TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Spero Therapeutics in a research report on Tuesday.

Spero Therapeutics Stock Performance

Shares of NASDAQ SPRO traded up $0.02 during mid-day trading on Thursday, reaching $1.28. 62,144 shares of the company’s stock were exchanged, compared to its average volume of 220,478. The firm has a market capitalization of $69.11 million, a price-to-earnings ratio of 2.98 and a beta of 0.63. Spero Therapeutics has a 52-week low of $0.99 and a 52-week high of $1.89. The company’s 50-day moving average is $1.37 and its 200-day moving average is $1.51.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $10.20 million for the quarter, compared to analyst estimates of $9.80 million. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. During the same quarter in the previous year, the company earned ($0.23) EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SPRO. Renaissance Technologies LLC increased its stake in Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after buying an additional 121,492 shares during the period. Acadian Asset Management LLC increased its position in shares of Spero Therapeutics by 40.6% during the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after acquiring an additional 309,262 shares during the period. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics in the first quarter valued at $31,000. Murchinson Ltd. grew its stake in Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares during the period. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.